Merck's Keytruda Combination Wins Expanded FDA Approval for Muscle Invasive Bladder Cancer
() -- Merck's (MRK) pembrolizumab, alone or with berahyaluronidase alfa-pmph, each in combination with enfortumab vedotin-ejfv, won US Food and Drug Administration approval on Friday as neoadjuvant treatment before surgery followed by adjuvant treatment after cystectomy for adults with muscle-invasive bladder cancer. T